MADISON,
Wis., Dec. 5, 2023 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the company has
initiated sales of the VitalHold™* package supporting
surface-guided radiation therapy (SGRT) on the Radixact®
System in Japan beginning
November 30, 2023. The VitalHold
feature incorporates SGRT capability on the Radixact System using
the Catalyst+ HD system manufactured by C-RAD, making it
possible to deliver deep inspiration breath hold (DIBH) treatments,
primarily for breast cancers, and perform markerless patient setup.
The addition of this new feature will enable medical teams using
the Radixact System to offer a wider range of radiotherapy
treatment options using one device.
SGRT is a technology that supports highly accurate positioning
by scanning the patient's body surface with a high-resolution
camera and reconstructing it as a 3D image in real-time. The
reconstructed image enables clinicians to easily visualize the
difference between the current body position and the target
position, helping to ensure high reproducibility of the patient
position during treatment.
Heart dose from left-sided breast radiotherapy has been
associated with a risk of cardiac injury1. In recent
years, DIBH irradiation has become the standard of care for the
treatment of left breast cancer to help minimize the heart dose.
DIBH is performed by asking the patient to take a deep breath to
physically separate the chest wall and targeted tumor from the
heart. SGRT technology, which helps confirm the patient is
appropriately positioned to deliver radiation, is widely used to
facilitate these treatments. SGRT may also help reduce stress on
the patient because it doesn't require permanent marks or lines on
their body to verify they are in the correct position.
"We are very pleased to now offer VitalHold to our customers to
support surface-guided radiotherapy using the Radixact System. With
its introduction, markerless patient setup is now possible, and
deep inspiration breath hold treatments can easily be performed to
care for people with breast cancer. This is expected to greatly
reduce the burden on medical staff and patients," said Juki Hozumi, President and General Manager of
Accuray Japan K.K.
Continued Mr. Hozumi, "Since the introduction of the
TomoTherapy® platform we have continued to enhance its
functionality. Now, the latest generation Radixact System is one of
the most versatile radiation delivery devices available and in the
Japanese market, there are over 100 units routinely used to treat
cancer. The VitalHold package is the newest feature of the Radixact
System and we are confident it will be used to treat many diseases,
including breast cancer. This technological innovation represents a
new step forward and we will continue to work to further contribute
to the advancement of radiotherapy."
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Madison, Wisconsin, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, X, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations and goals
regarding new products, services and innovations, patient
experiences and patient outcomes. These risks and uncertainties
include, but are not limited to, the effect of the current global
economic environment, including in connection to the COVID-19
pandemic, on the operations of the company and those of its
customers and suppliers; the company's ability to achieve
widespread market acceptance of its products; the company's ability
to develop new products or improve existing products to meet
customers' needs; the company's ability to anticipate or keep pace
with changes in the marketplace and the direction of technological
innovation and customer demands; reliance on third party
collaborators, partnerships, strategic alliances and joint
ventures; and such other risks identified under the heading "Risk
Factors" in the company's Quarterly Report on Form 10-Q, filed with
the Securities and Exchange Commission (the "SEC") on November 7, 2023, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408)
789-4426
bkaplan@accuray.com
*VitalHold availability is subject to regulatory clearance or
approval in some markets.
1 Deep Inspiration Breath Hold: Techniques and
Advantages for Cardiac Sparing During Breast Cancer Irradiation
- PMC (nih.gov)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-initiates-sales-of-the-vitalhold-solution-in-japan-supporting-surface-guided-radiation-therapy-on-the-radixact-system-302005518.html
SOURCE Accuray Incorporated